FOUNDED IN 1981 in Boston, Mass., Genzyme has evolved from a tiny startup to one of the world's leading biotech companies, with nearly 10,000 employees and operations in every region of the globe. Our products address rare genetic diseases, multiple sclerosis, cardiovascular disease and endocrinology; we maintain a substantial development program focused on these fields as well as other areas of unmet medical need. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
展开▼
